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ABSTRACT
Background: Measles vaccines (MV) have sex-
differential effects on mortality not explained by
protection against measles infection.
Objective: The authors examined whether whole-cell
diphtheriaetetanusepertussis (DTP) vaccine has sex-
differential and non-speciﬁc effects.
Data sources and eligibility: Following previous
reviews and a new search, the effect of DTP on
mortality up to the next vaccination was assessed in all
studies where DTP was given after BCG or DTP was
given after MV and there was prospective follow-up
after ascertainment of vaccination status.
Setting: High-mortality countries in Africa and Asia.
Methods: The initial observation of negative effect of
DTP generated six hypotheses, which were examined
in all available studies and two randomised trials
reducing the time of exposure to DTP.
Main outcome: Consistency between studies.
Results: In the ﬁrst study, DTP had negative effects on
survival in contrast to the beneﬁcial effects of BCG and
MV. This pattern was repeated in the six other studies
available. Second, the two ‘natural experiments’ found
signiﬁcantly higher mortality for DTP-vaccinated
compared with DTP-unvaccinated children. Third, the
femaleemale mortality ratio was increased after DTP
in all nine studies; in contrast, the ratio was decreased
after BCG and MV in all studies. Fourth, the increased
female mortality associated with high-titre measles
vaccine was found only among children who had
received DTP after high-titre measles vaccine. Fifth, in
six randomised trials of early MV, female but not male
mortality was increased if DTP was likely to be given
after MV. Sixth, the mortality rate declined markedly
for girls but not for boys when DTP-vaccinated
children received MV. The authors reduced exposure
to DTP as most recent vaccination by administering
a live vaccine (MV and BCG) shortly after DTP. Both
trials reduced child mortality.
Conclusions: These observations are incompatible
with DTP merely protecting against the targeted
diseases. With herd immunity to whooping cough, DTP
is associated with higher mortality for girls.
Randomised studies of DTP are warranted to measure
the true impact on survival.
ARTICLE SUMMARY
Article focus
- MV has sex-differential non-speciﬁc effects for
child survival. We examined whether DTP
vaccine has negative effects for survival, partic-
ularly for girls.
- We tested six hypotheses suggesting that DTP
may have negative health consequences if found
to be true.
- Furthermore, we conducted two randomised
trials reducing the time of exposure to DTP as
most recent vaccination by providing a live
vaccine shortly after DTP.
Key messages
- All available studies suggest that the effect of
DTP on child survival is opposite of the effects of
BCG and MV. In the two natural experiments,
DTP-vaccinated children had signiﬁcantly higher
mortality than DTP-unvaccinated children.
- AmongDTP-vaccinatedchildren,girlshavehigher
mortality than boys in all studies, whereas the
tendency is the opposite for BCG- and measles-
vaccinated children. DTP administered after MVin
randomised trials of MV is associated with
increased female but not male mortality.
- Reducing time of exposure to DTP as the most
recent vaccination with BCG or MV reduce child
mortality.
Strengths and limitations of this study
- Since the healthiest children are vaccinated ﬁrst,
one would expect DTP to be associated with
a beneﬁt. However, all the data suggest consis-
tently that DTP is associated with a negative
effect for girls.
- A randomised trial of the effect of DTP on overall
survival could not be conducted. There is a need
to conduct such studies now.
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Open Access ResearchINTRODUCTION
Overall, routine vaccinations have beneﬁcial effects on
child survival in high-mortality countries.
1 It is assumed
that the effect on child survival is proportional to vaccine
efﬁcacy and the burden of the targeted infection.
2
However, routine vaccinations may have non-speciﬁc
effects (NSE) on child survivaldthat is, effects not
explained by prevention of the vaccine-targeted
infections.
134Such effects are presumably due to
vaccines affecting susceptibility to unrelated infections.
NSE were initially demonstrated by the high-titre
measles vaccine (HTMV) incident. Though protective
against measles infection, HTMV was associated with
a twofold increased female mortality if the children got
diphtheriaetetanusepertussis (DTP) after HTMV.
5 In
contrast, standard measles vaccine (MV) is associated
with a reduction in mortality, which is not explained by
prevention of acute measles infection,
6e20 and with
reduced mortality for girls relative to boys
5 7 13 17 21e31;
for example, the femaleemale mortality rate ratio
(MRR) declined from approximately 1.00 to 0.65 after
the ﬁrst MV campaigns in two rural areas of Senegal.
13 17
Following the studies of HTMV and standard MV, we
examined the NSE of other vaccines.
13 2 e81 BCG was
associated with a beneﬁcial effect on mortality, whereas
DTP had no such effect, the effects being statistically
different for the two vaccines.
1 Subsequent studies
corroborated that BCG has beneﬁcial effects for girls.
38 40
On the other hand, DTP appeared to have a negative
effect for girls.
26
With the increasing evidence for NSE of vaccines, the
Working Group on the Non-speciﬁc Effects of Vaccines
(WGNSEV) has formulated and prioritised six trials,
which would help to optimise the current vacc-
ination schedules so that they maximise the reduction in
child mortality in high-mortality areas.
82 Two priority
trials to examine the beneﬁcial NSE of BCG and MV have
now been completed.
36 57 9In trials of BCG at birth versus
delayed BCG among low birth weight (LBW) children,
neonatal mortality was reduced by 48% (95% CI 18% to
67%) (WGNTEV, trial 1).
65 79 In a large trial of an addi-
tional dose of MV at 4.5 months of age,
3 per-protocol
analysis showed that children receiving two doses of MV
at 4.5 and 9 months of age had a 30% lower mortality
between 4.5 and 36 months of age than children
receiving the currently recommended single dose of MV
at 9 months of age (WGNTEV, trial 2). There was
a negative interaction with neonatal vitamin A supple-
mentation (VAS): among the children who had not
received VAS, the reduction in mortality was 50%
between 4.5 and 36 months of age. When cases of measles
infection were excluded, the reduction in mortality was
45%. With such strong support for the importance of the
beneﬁcial NSE of live vaccines, there are good reasons
to examine carefully the possible negative NSE of inac-
tivated whole-cell DTP.
Though several meta-analyses have shown that well-
conducted observational studies can provide the same
results as randomised trials,
83 84 observational studies
have historically ranked lower as evidence for a treatment
effect than randomised studies. Hence, it is desirable to
conduct randomised studies to test the NSE of vaccines,
including the possible negative effect of DTP. However,
once a vaccine is recommended by WHO, it becomes
difﬁcult to withhold the vaccine in randomised trials to
measure the NSE of the vaccine. A possible way to test
DTP would be to randomise children to either the
current regimen of vaccination at 6, 10 and 14 weeks of
age or to delayed vaccination at 6e8 months of age just
before measles vaccination at 9 months of age (WGNSEV,
trial 6). However, this has been deemed unethical by
WHO committees.
85 Hence, the hypothesis that DTP has
a negative effect on mortality can only be tested indi-
rectly, ﬁrst by making logical deductions about epidemi-
ological trends and testing these in other data sets and,
second, by testing the implications in randomised trials.
The more deductions can be generated and found to be
consistent in unrelated data sets, the more likely it is that
the underlying hypothesis represents a causal process.
We have tested our initial observation that DTP was
associated with increased mortality
1 in several other data
sets and subsequently generated ﬁve new deductions.
These six linked observations suggest that DTP increases
mortality in girls in areas with herd immunity to
whooping cough. Hence, reducing exposure to DTP as
the most recent vaccination should reduce child
mortality. In two randomised trials, we tested whether
reducing exposure to DTP by vaccinating with MV at
4.5 months of age after DTP3 (WGNSEV, trial 2) and by
BCG revaccination at 19 months after DTP booster
vaccination (WGNSEV, trial 3) reduced child mortality.
This proved to be the case in both trials.
METHODS: MATERIALS AND ASSUMPTIONS
The initial hypothesis about a negative effect of DTP on
child survival was formulated in a paper published in
2000.
1
Data sources
There have been very few studies of routine immunisa-
tions and their effect on child mortality in high-mortality
countries. A previous WHO-sponsored literature review
from 2001
2 found only two studies of the effect of DTP
on mortality.
11 8During the last 10 years, several new
studies have become available and studies of DTP and
mortality have been reviewed three times.
61 81 86 In 2011,
we conducted a new PubMed search for publications on
‘mortality’ or ‘death’ in relation to one of the vaccine
terms ‘DTP’, ‘DPT’, ‘diphtheria-tetanus-pertussis’ or
‘pentavalent vaccine’ (see supplementary ﬂow diagram).
To be relevant, a study had to report total mortality
following DTP vaccination in a deﬁned population of
children in high-mortality countries (Africa and Asia).
The methodological exclusion criteria are discussed
below. This search identiﬁed 444 papers: based on
reading the abstract or paper, 122 papers were classiﬁed
2 Aaby P, Benn C, Nielsen J, et al. BMJ Open 2012;2:e000707. doi:10.1136/bmjopen-2011-000707
Non-speciﬁc effects of DTPas reviews, commentaries and cost-effectiveness analyses
without primary data; 99 papers were not from a high-
mortality country in Africa or Asia; 117 papers had no
mortality data or were not about children; 43 papers
were not related to DTP and 33 papers were disease-
speciﬁc studies or case reports. Hence, we retained 30
studies, and an additional ﬁve studies were known from
vaccine reviews or other sources.
91 84 77 88 7These studies
are brieﬂy presented in tables 1 and 2. Most of the
identiﬁed studies were conducted in Guinea-Bissau or
were reanalyses of data from longitudinal studies in
Africa, including studies from Congo,
22 Gambia,
31
Ghana,
74 Malawi,
30 53 Senegal
5 and Sudan
22 (tables 1
and 2). Seven studies were a result of WHO’s Global
Advisory Committee on Vaccine Safety request that other
groups reanalyse existing data sets to examine the effect
of DTP on child mortality.
44e49 58 Fourteen studies
had information on DTP provided before MV (table 1);
two studies were partly overlapping,
35 2so only one of
them was used in the hypothesis-speciﬁc tables.
52 Three
studies had speciﬁc morbidity but no mortality data
(table 1). Nine studies had information on mortality
when DTP was administered after MV (table 1). Nine
studies were not used for the reasons discussed in the
following paragraph. Table 1 indicates whether the
studies had general and sex-speciﬁc mortality rates or
only data from caseecontrol and hospital case death
studies with no follow-up.
Study exclusion criteria
We excluded studies that had survival bias and studies in
which DTP had been administered with BCG or MV. First,
in our previous review of DTP and mortality,
61 studies
with retrospective updating of vaccine information had
survival bias which produced misleading estimates of the
effect of DTP
60 61 (table 2). Second, the recommended
vaccination schedule used in Bissau while most of these
studies were conducted is depicted in ﬁgure 1.O u r
hypothesis has focused on vaccinations, which have been
administered in the sequence recommended by
WHO: BCG ﬁrst, followed by three doses of DTP and oral
polio vaccine (OPV) and then MV (ﬁgure 1). However,
delays in vaccination programmes are common and
vaccinations are often given simultaneously: BCG with
DTP or DTP with MV.
44 45 47 48 58 77 These combinations
have different NSE.
22 28 53 57e59 64 66 77 Hence, studies in
which most children received BCG and DTP simulta-
neously or DTP and MV simultaneously were not
included (see table 2).
Analyses
The issues associated with analysing incomplete vacci-
nation data have been presented more fully in an
appendix (supplementary material). Many studies have
analysed simultaneously the effect of several vaccines
over several years, for example, 2 or 5 years of age.
44e48
This would be appropriate if each vaccine had an inde-
pendent and permanent programming effect on the
immune system. However, the NSE of vaccines appar-
ently inﬂuence general susceptibility to infectious
diseases and that effect seems to be strongest while
a vaccine is the most recent vaccination.
81 We therefore
focused on studies in which the effect of a speciﬁc
vaccine could be analysed from the time it was admin-
istered until the next vaccine was given.
In most survival analyses, the estimates of the effects
of vaccines on survival are obtained by comparing
mortality at the same age for vaccines, which are recom-
mended to be given sequentially. This comparison is
inherently biased (‘frailty bias’) because the healthiest
children are likely to receive the recommended vaccine
ﬁrst (see appendix). Comparisons of sequential vacci-
nations should be interpreted cautiously. However, if
a vaccine, in spite of the expected lower mortality, is
associated with a higher mortality than the previous
vaccine, this is an indication that the vaccine in ques-
t i o nm a yb ea s s o c i a t e dw i t ha na b s o l u t ei n c r e a s ei n
mortality. We have also emphasised the comparison of
female and male mortality rates among children who
have received the same vaccine. In the pre-vaccination
era, post-neonatal child mortality was similar for
boys and girls in West Africa (ﬁgure 2). All data from
Africa also suggest that girls and boys are treated
equally with respect to vaccination, the age of vaccina-
tion and coverage being the same for boys and girls.
In these circumstances, a deviation of the femaleemale
MRR from 1.0 for children who have received a speciﬁc
vaccine as the most recent vaccination would sug-
gest that this vaccine is associated with sex-differential
NSE.
Statistical analyses
Estimates are presented as reported in the published
papers or have been calculated based on the deaths and
person-years reported in the papers. Tests for interaction
have been used to assess whether MRR for different
vaccines were similar for vaccinated versus unvaccinated
children and for girls versus boys.
Presentation
For each of the six deductions, we present a short
section on the deduction which generated a new
hypothesis and how studies were selected, a section on
the observations which followed the hypothesis and
a section discussing possible methodological problems
and conclusions in relation to the observation. The
development of the hypotheses is summarised in ﬁgure
3. The sequence of presentation follows more or less
the sequence in which these hypotheses were gener-
ated: observations IeIII deal with the effect of DTP
when administered after BCG (or no vaccine) and
observations IV and V with the effect of DTP admin-
istered after MV. Observation VI relates to the effect on
female mortality of changing from DTP to MV vacci-
nation. Finally, we present the two trials, which were
conducted to reduce the duration of exposure to DTP
as the most recent vaccination.
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Non-speciﬁc effects of DTPRESULTS
Developing the hypothesis: DTP has negative NSE and
sex-differential effect on child survival
As described under the Methods section, 444 studies
were screened for inclusion and 35 were retained as
potentially relevant to the ﬁnal analyses (tables 1 and 2).
Observation I. Contrasting effects of DTP, BCG and MV
Deduction and study selection
Unexpectedly, a study from rural Guinea-Bissau reported
differential effects of DTP, BCG and MV within the same
population
1; mortality was low after BCG, increased after
the ﬁrst DTP vaccination (DTP1) and reduced again
after MV. We tested the pattern of contrasting MRR for
different vaccines in all studies that reported data on the
primary DTP vaccination (after BCG and before MV) as
well as BCG and/or MV vaccinations (see table 1).
Observation
A caseecontrol study from Benin
18 had previously
reported the same tendencies in relative mortality for
the three vaccines (ﬁgure 4). We tested these trends in
a further ﬁve studies. All studies found the same pattern:
mortality was low after BCG and MV but increased after
DTP vaccination (ﬁgure 4, supplementary table 2). The
difference in effect on survival of BCG versus DTP was
statistically signiﬁcant in six of six studies and for DTP
versus MV in three of ﬁve studies. DTP vaccination
compared with no DTP vaccination was associated with
increased mortality in all seven studies, being signiﬁcant
in three studies.
In most studies, DTP-unvaccinated children had
received BCG. However, in the ﬁrst 2 years of the study of
the introduction of DTP in the rural areas of Guinea-
Bissau,
42 only 36 children had received BCG. If the BCG-
vaccinated children were excluded, DTP-vaccinated chil-
dren had a mortality rate of 14.7 per 100 person-years (27/
183.4) compared with 5.3 per 100 person-years (9/169.4)
for the DTP-unvaccinated children, the adjusted MRR
being 2.62 (95% CI 1.08 to 6.35); the negative effect was
similar for girls (MRR ¼2.63 (95% CI 0.76 to 9.05)) and
boys (MRR ¼2.60 (95% CI 0.85 to 7.94)) (unpublished
data). Hence, DTP may be associated with increased
mortality either when it is given to previously unvaccinated
children or to children who have previously received BCG.
Methodological considerations and implications
In the initial study,
1 the trends were strong enough to
document a differential effect of BCG and DTP, even
though we did not limit the analysis to the most recent
vaccination but used a landmark approach with multi-
variable analysis to estimate the effect of BCG and DTP
in the same age range. A stricter censoring of the
observational period to the age range in which DTP
predominates would have provided stronger estimates:
for example, the MRR estimate for DTP2 and DTP3 was
reported to be 1.38 (95% CI 0.73e2.61)
1 but became
1.75 (95% CI 0.86 to 3.59) when follow-up was restricted
to 9 months to reduce the confounding effect of MV,
which is usually given at 9 months of age.
50
BCG         DTP/OPV                                       measles                                   DTP/OPV booster
OPV
Birth        6     10     14 week                                 9 months                                       18 months
Figure 1 Vaccination schedule in Guinea-Bissau. Note: the
vaccination schedule in Guinea-Bissau was changed in 2008.
Pentavalent vaccine (DTP + hepatitis B virus + Hib) has replaced
DTP, yellow fever is administered with measles vaccine and the
booster doses of DTP and OPV have been removed. DTP,
diphtheriaetetanusepertussis; OPV, oral polio vaccine.
Figure 2 Femaleemale
mortality ratios in community
studies from the prevaccination
era in West Africa (see
supplementary table 1).
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Non-speciﬁc effects of DTPDTP and OPV are usually given together, and it is
therefore difﬁcult to distinguish the effects of these
vaccines. However, when we ﬁrst introduced DTP in
rural areas of Guinea-Bissau, the effect was particularly
strong during the ﬁrst year when no OPV was available
and only DTP was administered.
42 In a second study,
43
DTP administered with OPV had a worse effect than
OPV alone. Furthermore, when only OPV was given
Initial observation: 
HTMV associated with 
increased female mortality5  
Hypothesis: Do routine 
vaccines have non-
specific and sex-
differential effects? 
Observation: 
Standard MV associated 
with decreased mortality, 
particularly for girls11   
DTP observation 1: 
MV and BCG associated 
with reduced mortality, 
but DTP is not1  
Question: Is the negative 
effect of DTP also seen 
in situations without 
selection bias to 
vaccination? 
DTP observation 2: 
DTP associated with 
increased mortality in 
two “natural 
experiments” with 
limited selection42 43  
Question: Does DTP 
have sex-differential 
effects? 
 
DTP observation 3: 
Female–male MR increased 
if DTP is the most recent 
vaccine 26–28 31 42 53 54
DTP observation 3: 
Compared with vaccinated 
boys, girls had low mortality 
after BCG, high mortality 
after DTP, and low mortality 
after MV26–28 31 53  
Question: Could a 
negative effect of DTP 
in females explain the 
increased mortality after 
HTMV? 
 
DTP observation 4: 
The increased female 
mortality after HTMV 
was only in girls who 
had received DTP or 
IPV after HTMV5   
Question: Is DTP after 
MV also associated with 
increased female 
mortality? 
DTP observation 5: 
In six randomised trials 
of early MV, the female 
mortality rate was increased 
if DTP was likely given 
after MV22 51 78  
DTP observation 6: 
The female mortality rate 
declined once the DTP 
vaccinated girls received 
MV 26 31 53  
Figure 3 The research process. DTP, diphtheriaetetanusepertussis; HTMV, high-titre measles vaccine; MV, measles vaccine.
Figure 4 Mortality ratios for
different routine vaccinations
within the same study
(observation I) (see
supplementary table 2). DTP,
diphtheriaetetanusepertussis;
MV, measles vaccine.
0.55 (0.36 to 0.85)
1.84 (1.10 to 3.10)
0.48 (0.27 to 0.87)
0.68 (0.38 to 1.23)
2.20 (0.93 to 5.22)
0.55 (0.28 to 1.07)
0.63 (0.30 to 1.33)
1.92 (1.04 to 3.52)
NA
NA
2.32 (0.53 to 10.0)
0.51 (0.27 to 0.98)
0.11 (0.02 to 0.69)
1.58 (0.36 to 7.02)
0.44 (0.20 to 1.00)
0.45 (0.16 to 1.23)
3.19 (0.80 to 12.8)
0.42 (0.16 to 1.14)
0.55 (0.35 to 0.89)
4.33 (1.58 to 11.9)
NA MV
DTP
BCG
MV
DTP
BCG
MV
DTP
BCG
MV
DTP
BCG
MV
DTP
BCG
MV
DTP
BCG
MV
DTP
BCG
Guinea-Bissau64 65
Malawi53
Guinea-Bissau26
Guinea-Bissau27
Guinea-Bissau42 
Benin18 
Guinea-Bissau1 
0.1 0.2 0.3 0.5 1 2 3 5 10
Mortality rate ratio
12 Aaby P, Benn C, Nielsen J, et al. BMJ Open 2012;2:e000707. doi:10.1136/bmjopen-2011-000707
Non-speciﬁc effects of DTPduring a polio eradication campaign, the impact of OPV
was, if anything, beneﬁcial.
36 Hence, we assume that any
negative effect of combined DTP and OPV vaccination is
due to DTP.
It has been proposed that a negative effect of DTP
could be due to sick children getting vaccinated ﬁrst
because they come more frequently to be treated at
health centres.
18 90 91 However, both nurses and mothers
are usually reluctant to vaccinate sick children.
42 46 67 If
the increased mortality among DTP-vaccinated children
occurred because sick children had been preferentially
recruited for the DTP group, then there should have
been a non-random clustering of deaths in the DTP
group. This was not the case.
26 42 For example, in the
study of the introduction of DTP,
42 it was noted that the
median time to death was 95 days in the DTP group and
80 days in the unvaccinated group. The survival curves in
the studies comparing DTP-vaccinated and DTP-unvac-
cinated children also indicate that there is no clustering
of early deaths in the DTP group.
14 25 36 4Consistent
with the tendency of nurses and physicians not to
vaccinate sick children, current data suggest that DTP
vaccination is associated with a strong positive selection
bias, with healthier and wealthier children coming ﬁrst
for vaccination.
14 25 36 4Due to ‘frailty bias’ among the
DTP-unvaccinated children, DTP should be expected to
be associated with a beneﬁcial effect on child survival.
The opposite effect of DTP observed in all studies in
ﬁgure 4 is therefore worrying. Furthermore, BCG and
MV are associated with a beneﬁcial effect, and it is
therefore unlikely that a negative selection bias for being
vaccinated explains the effect of DTP. Hence, since DTP
is associated with a higher mortality than BCG, the data
in ﬁgure 4 clearly suggest that DTP is associated with
increased mortality. BCG, DTP and MV have different
effects on survival, and since BCG and MV have been
found in randomised trials to have a beneﬁcial NSE,
DTP apparently has a negative NSE.
Observation II. Comparing DTP-vaccinated and DTP-
unvaccinated children in studies with limited selection bias
Deduction and study selection
The consistently opposite effect of inactivated DTP
compared with live BCG and MV suggested that
mortality might be increased after DTP vaccination. A
small randomised trial of MV used DTP as a control
vaccine; three of 27 DTP-vaccinated children died
during 18 months of follow-up compared with none of
26 measles-vaccinated children.
9 No large-scale rando-
mised study has examined the impact of DTP vaccine on
survival. In the absence of randomised trials, we looked
for studies with limited selection bias with respect to who
received or did not receive DTP. Among the studies
indicated in table 1, only two studies could be said to
have limited self-selection for DTP vaccination.
42 43
Observations
First, the Bandim Health Project introduced DTP in
20 villages in rural Guinea-Bissau in the mid-1980s, at
a time when vaccines were not generally available in
rural areas. This is the only study in the global literature
of what happened when DTP was introduced in a high-
mortality country. Controlling for background factors,
the DTP-vaccinated children had a twofold higher
mortality (MRR¼1.92 (95% CI 1.04 to 3.52)) during
6 months of follow-up compared with DTP-unvaccinated
children, even though unvaccinated children had worse
nutritional status.
42 Some children were travelling when
the team visited the villages every sixth months, some
had fever and were therefore not vaccinated, and
vaccines were not available at some visits.
42 Unvaccinated
children had limited access to vaccination elsewhere
until our next visit.
In a second study, DTP was not available in several
periods in Bissau city in 2001. Some children, who were
due to receive DTP and OPV, received only OPV when
they came for vaccination to a health centre, whereas
others received both vaccines. We compared the case
death of hospitalised children at the only paediatric
ward in Bissau according to their vaccination status.
Children who had received both OPV and DTP as their
most recent vaccines had a signiﬁcant threefold higher
case death compared with children who had received
OPV but not DTP when they had come to a health
centre. The case death was threefold higher for both
boys and girls, though this difference was not statistically
signiﬁcant for either boys or girls individually (unpub-
lished data). Controlling for background factors did not
change the estimate.
43 67
Methodological considerations and implications
Several observational studies have estimated the effect of
DTP without survival bias (ﬁgure 4). Since these studies
did not ﬁnd the expected beneﬁt for DTP-vaccinated
compared with DTP-unvaccinated children, DTP may
have negative effects on child survival. The negative
effect of DTP in the two studies with limited self-selec-
tion for DTP vaccination was not due to sick children
being more likely to receive DTP vaccination.
90 DTP-
vaccinated children had slightly better nutritional status
in both studies and few
42 or no vaccines
43 were given
during follow-up. Hence, these two studies provide
further support for the hypothesis that DTP is associated
with an increase in mortality rate.
Observation III. Sex-differential effects of DTP
Deduction and study selection
HTMV, MV and BCG have sex-differential effects.
51 14 0
We therefore examined whether DTP had sex-differen-
tial effects. Nine of the 13 studies of DTP before MV
(table 1) had information on sex-speciﬁc mortality
rates.
1 9 18 43
Observations on mortality
The studies of the relative mortality of girls and boys
after DTP administered before MV are summarised in
ﬁgure 5 (supplementary table 3). Girls had higher
mortality than boys in all nine studies, the difference
being statistically signiﬁcant in four studies. In nearly all
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Non-speciﬁc effects of DTPstudies, DTP was administered after BCG. In the two
studies in which some children had received VAS, the
femaleemale MRR was higher among those who had
received VAS than among those who had received
placebo (supplementary table 3). In the study of vacci-
nation status and in-hospital mortality,
27 the sex-differ-
ential effect of DTP applied to all major disease
categories, including pneumonia, diarrhoea and
presumptive malaria. The three studies with mortality
data for unvaccinated children suggested a slightly lower
mortality for unvaccinated girls than for unvaccinated
boys, but the difference was not statistically signiﬁcant.
In all studies that had information on DTP as well as
BCG or MV, the femaleemale MRR was low after BCG
and MV vaccinations and high after DTP (ﬁgure 6). The
difference in the femaleemale MRRs between DTP and
MV was statistically signiﬁcant in ﬁve of ﬁve studies
(supplementary table 4).
Figure 5 Femaleemale (F/M)
mortality ratios for
diphtheriaetetanusepertussis
(DTP)-vaccinated children in
studies of DTP administered after
no previous vaccine
42 or after
BCG (other studies) and before
measles vaccine (observation III)
(see supplementary table 3).
Figure 6 Femaleemale mortality
ratios for diphtheriaetetanuse
pertussis (DTP)-, BCG- and
measles vaccine (MV)-vaccinated
children (observation III) (see
supplementary table 4).
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Non-speciﬁc effects of DTPObservations on morbidity
In community studies with complete information on
vaccinations, the femaleemale incidence rate ratio
among DTP-vaccinated children was 6.25 (95% CI 2.06 to
18.9) for cryptosporidium, 1.93 (95% CI 0.89 to 4.21) for
rotavirus infection, 1.51 (95% CI 1.04 to 2.20) for infec-
tion with other diarrhoea-causing enteropathogens and
1.32 (95% CI 1.03 to 1.70) for infection with enter-
opathogens not causing diarrhoea.
55 56 In one study of
measles infection, the femaleemale RR for hospitalisation
varied signiﬁcantly depending on the most recent vacci-
nation, being 1.21 (95% CI 0.82e1.77) for DTP before
MV and 0.28 (95% CI 0.11e0.68) for MV alone.
75
Methodological considerations and implications
Several trials of early MV before 9 months of age have
had a control group of children who were not measles
vaccinated before 9e10 months of age.
72 25 1These
studies were not included in the present analysis of the
sex-differential effect of DTP as most studies used
another vaccine as a ‘control’ vaccine. In the studies
using inactivated polio vaccine (IPV) as the control
vaccine, the femaleemale MRR was 1.52 (95% CI 1.02 to
2.28) between enrolment and the receipt of MV.
51 In
Senegal, where the control group received placebo at
the same time as DTPeIPV at 5 months of age, the
femaleemale MRR was 1.41 (95% CI 0.53 to 3.76)
between 5 and 10 months of age. However, since most
children in Senegal had received DTP and BCG simul-
taneously, the study was not included in ﬁgure 5.
It could be suggested that girls have a higher
mortality than boys in the age group in which DTP
predominates and that the sex-differential effects of
DTP vaccination are age speciﬁc rather than vaccine
related. We therefore compared mortality or morbidity
rates of DTP and MV-vaccinated boys and girls within
the same age group in the studies with relevant
data
26e28 55 (ﬁgure 7). In all studies, the femaleemale
mortality or morbidity ratio was high after DTP and low
after MV, the difference being statistically signiﬁcant in
three of ﬁve studies (supplementary table 5). Hence,
the pattern is more likely to be vaccine speciﬁc than
age speciﬁc.
The higher relative mortality of DTP-vaccinated girls
compared with DTP-vaccinated boys in these studies is
not merely a trivial repetition of the same study design
with the same potential biases. Very different study
designs were used, including studies of femaleemale
twin pairs,
28 vaccination cards collected after death,
31
vaccination status measured just before a war period with
high mortality,
26 vaccination status assessed at hospital-
isation
27 and children receiving DTP at discharge from
a hospital.
54 It cannot be explained by nutritional status
because girls did not have worse nutritional status than
boys at DTP vaccination (data available upon request).
The contrasting femaleemale MRRs between DTP and
BCG or MV also excludes the possibility that the higher
femaleemale MRR after DTP was due to a generally
higher female mortality rate in Africa. Since most of the
present studies (ﬁgures 5 and 6) also documented
increased mortality of DTP-vaccinated children relative
to BCG- and MV-vaccinated children (ﬁgure 4), the
higher female than male mortality rates or case death
ratios for DTP-vaccinated children presented in supple-
mentary tables 3e5 cannot be explained by a beneﬁcial
effect of DTP for boys. Hence, these studies support the
hypothesis that DTP is associated with increased female
mortality when DTP is given after BCG.
Figure 7 Mortality or morbidity
patterns among
diphtheriaetetanusepertussis
(DTP)-vaccinated and measles-
vaccinated children of similar age
(observation III). One additional
study of femaleemale twins could
not be presented graphically
because one group had no deaths;
this study had signiﬁcant
differential effects of DTP and MV
(see supplementary table 5).
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Non-speciﬁc effects of DTPObservation IV. HTMV trials and DTP
Deduction and study selection
The consistent sex-differential effects of DTP suggested
a solution to an earlier enigma. In the late 1980s, rando-
mised trials found that HTMV administered at 4e5
months of age was associated with a twofold higher
mortality in girls.
5 Control children received IPV or
placebo at 4e5 months of age plus standard-titre MV at
9e10 months of age. Though girls have a lower mortality
after standard MV (observation III), HTMV-vaccinated
girls had a higher mortality than HTMV-vaccinated boys
and a higher mortality than control girls after 9e10
months of age (when control children had received
standard MV). HTMV was administered early, and most
children received DTP/IPV after MV. We examined
whether DTP/IPV administered after HTMV could
explain the increased female mortality in all the HTMV
trials with information on vaccinations after HTMV.
52 29 2
Another HTMV study with mortality data was performed
in Haiti,
29 but DTP vaccination status was not reported.
Observations
In a reanalysis of all the West African trials, we found no
increase in the femaleemale MRR for children who did
not receive the planned DTP/IPV vaccination after
HTMV (femaleemale MRR ¼0.96 (95% CI 0.69 to
1.34)). In contrast, twice as many girls as boys died
among children who received DTP/IPV after HTMV.
5
Girls in the HTMV group who received DTP/IPV at
9e10 months of age had an MRR of 2.35 (95% CI 1.41 to
3.91) from 9 months to 5 years of age compared with
control girls receiving standard MV at the same age.
5
Hence, the real cause of increased female mortality after
HTMV was probably that most children received DTP
after being given HTMV at 4e5 months of age, while
control children received DTP before being given stan-
dard MV at 9 months of age.
We tested this further in a reanalysis of the two other
African studies of HTMV with mortality data.
22 92 First, in
Congo, children did not receive DTP after HTMV and
girls had no excess mortality, the femaleemale MRR
being 0.40 (95% CI 0.13 to 1.27). Second, in Sudan,
children did receive DTP after HTMV, and the femalee
male MRR was 3.89 (95% CI 1.02 to 14.83) from
5 months to 3 years of age. This study collected data on
vaccination status at enrolment but not on vaccinations
during follow-up. Excess female mortality was found only
among children who had not received all doses of DTP
prior to enrolment and so presumably received missing
doses during follow-up. The excess female mortality
increased signiﬁcantly with the number of doses of DTP
missing at enrolment and therefore likely to be given
during follow-up. Hence, DTP is likely to have caused
the increased female mortality.
Methodological considerations and implications
The hypothesis that DTP causes excess female mortality
after BCG generated the deduction that the excess
mortality in the HTMV trials could be due to a similar
process of DTP vaccinations causing excess female
mortality after HTMV. HTMV-vaccinated girls who
received DTP/IPV after HTMV were found to have
higher mortality than both HTMV-vaccinated boys
who received DTP/IPV after HTMV and control girls
who had received MV later in infancy. Since girls who
received DTP/IPV after HTMV had higher mortality
than control girls receiving MV at 9e10 months of age,
the increased femaleemale MRR after HTMV cannot be
ascribed to reduced mortality among boys who received
DTP/IPV after HTMV. Hence, HTMV may have been
withdrawn for the wrong reason. The increased mortality
among girls after HTMV appears to have been caused by
the administration of inactivated vaccines after HTMV
and not by a direct effect of HTMV itself.
Observation V. DTP after measles vaccination associated with
increased female mortality
Deduction and study selection
The Sudan trial
22 suggested that the number of missing
DTP vaccinations prior to MV explained the subsequent
excess mortality of girls in this trial. We therefore tested
whether missing doses of DTP at enrolment was associated
with increased female mortality in other trials of MV,
which had documented DTP vaccination status at the time
of enrolment, and where DTP and MV were not admin-
istered simultaneously. Apart from the Sudanese study,
22
information was available from ﬁve other MV trials: one
from Congo
22 and four from Guinea-Bissau.
51 The four
trials from Bissau covered all MV trials conducted in
Bissau before we introduced the requirement that chil-
dren had to have received DTP3 prior to enrolment.
3
Furthermore, we reviewed observational studies of DTP
administered after MV (tables 1 and 2). Several studies
have information on DTP and MV administered simulta-
neously,
22 31 53 57 66 77 but only three studies had infor-
mation on DTP administered after MV.
31 57 74
Observations
In the six randomised trials of early MV compared with
children who had received DTP3 at enrolment, mortality
was signiﬁcantly increased among children who were
missing DTP3 at enrolment (and presumably received
additional doses of DTP after MV) with a MRR of 1.60
(95% CI 1.14 to 2.24) (ﬁgure 8). However, the negative
effect was found only for girls. Compared with children
who had received DTP3 prior to MV, girls likely to
receive DTP after MV had a MRR of 2.36 (95% CI 1.43 to
3.89), whereas there was no difference for boys. The
effect was signiﬁcantly different for girls and boys
(p¼0.031, test of homogeneity) (supplementary table 6).
The observational studies also suggested that DTP after
MV is associated with increased female mortality. In
a large trial of VAS after 6 months age in Ghana,
74 the
femaleemale MRR was 1.62 (95% CI 1.02 to 2.63) during
the 2 years of the study among children who had received
only one to two doses of DTP and were likely to receive
DTP during follow-up. The excess female mortality in this
study was also stronger among the children who received
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Non-speciﬁc effects of DTPVAS rather than placebo. At the paediatric ward in Bissau,
children who had received DTP after MVrather than MV
alone as the most recent vaccination had an increased in-
hospital mortality and the trend was stronger for girls,
though the effect was not statistically signiﬁcant in this
smallstudy.
43InaGambiancommunity study,vaccination
cards were collected in connection with a verbal autopsy
interview: measles-vaccinated girls who died were 3.34
(95% CI 1.15 to 9.74) fold more likely to have received
DTP3 after MV than girls who did not die.
31
Methodological considerations and implications
The six measles trials did not register all vaccinations
during follow-up. However, most children did receive the
missing doses of DTP: at least 85% received missing
doses of DTP in Guinea-Bissau.
51 In general, children
missing doses of DTP might have less compliant mothers
or have less access to healthcare and therefore have
higher mortality during follow-up. However, these chil-
dren were enrolled in trials and had the same access to
healthcare, and it seems unlikely that minor delays in the
administration of DTP can explain the differences in
mortality. Furthermore, the effect was found only for
girls, making it unlikely that the overall effect is due to
selection bias. The few other studies with information on
mortality for children who had received DTP after MV
also suggested a stronger negative effect for girls. Hence,
the data suggest that administration of DTP after MV
increases mortality and that this effect is stronger in girls
than boys.
Observation VI. Mortality declines when DTP-vaccinated girls
receive MV
Deduction and study selection
Without a control group, it is difﬁcult to ascertain the
overall effect of DTP on child mortality. However, the
increased femaleemale mortality ratio after DTP and
the reduced ratio after MV (ﬁgure 6) suggested that
mortality would decline for girls once they receive MV.
We therefore assessed the change in mortality levels for
boys and girls in the transition from DTP to MV. There
were three community studies among the studies in
observation III (ﬁgure 6) with information on both DTP
and MV mortality rates.
26 31 53
Observations
In the transition from DTP to MV, mortality decreased
for girls in all three studies (ﬁgure 9). This pattern is
illustrated for two of the studies in ﬁgure 10. For boys,
mortality increased in two studies and declined less
markedly than for girls in one study. The effect of MV
was statistically different for boys and girls in two of the
three studies (supplementary table 7).
Methodological considerations and implications
In two studies, we used data for individuals with known
vaccination status within the respective age groups. In
the Gambia, it was known that the coverage was very high
but individual vaccination data were not available and
the comparison could therefore only be made for all
children in the age groups. We analysed the community
data sets used in ﬁgure 6, and girls experienced
a pronounced decrease in overall mortality when MV
replaced DTP. As discussed above, this change could not
be ascribed to an age effect (ﬁgure 7).
Testing the hypothesis: the negative effect of DTP may be
reduced with a subsequent vaccination with MV or BCG
The six observations in this paper support the hypothesis
that DTP has negative NSE and sex-differential effect
on child survival. It has been considered unethical to
test DTP in a randomised study.
85 Instead we tested
Figure 8 Mortality after
enrolment in measles vaccination
trials according to
diphtheriaetetanusepertussis
(DTP) status at enrolment:
missing DTP vaccinations versus
fully DTP vaccinated (observation
V) (see supplementary table 6
with two additional small studies
which could not be presented due
to undeﬁned estimates).
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Non-speciﬁc effects of DTPan implication of the hypothesis in two randomised
trials.
36 9
Deduction
If overall mortality is increased when DTP is the pre-
dominant vaccine (observations I, II and VI), it might
reduce mortality if a live vaccine were given shortly after
DTP to change the immunological proﬁle and reduce
exposure to DTP as most recent vaccine. As shown in
ﬁgure 10, which presents data from The Gambia and
Malawi, mortality is increased between 2 and 8 months of
age (especially in girls), the age at which DTP is likely to
be the most recent vaccine, and around 18 months of
age, the age at which booster DTP vaccination has been
administered in The Gambia. Hence, mortality might be
reduced if MV were administered earlier than 9 months
of age or a BCG revaccination was given shortly after the
18 months booster dose of DTP.
First test: early measles vaccination
We conducted a randomised trial of an additional dose
of MV at 4.5 months of age to test whether early MV is
associated with reduced mortality for girls.
3 To prevent
the problem with increased mortality among girls getting
DTP after MV,
51 only children who had already received
DTP3 were enrolled in the trial.
36 8Compared with the
control children who had DTP3 as the most recent
vaccination, MV tended to have a beneﬁcial effect for
girls, the MRR between 4.5 and 9 months of age being
0.46 (95% CI 0.19 to 1.11) for girls and 0.94 (95% CI
0.44 to 2.01) for boys.
3 Many of the children in this trial
had received VAS at birth, and VAS had a negative effect
Figure 9 Mortality rate ratios for
measles vaccine age group versus
diphtheriaetetanusepertussis age
group (observation VI) (see
supplementary table 7).
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Figure 10 Age- and sex-speciﬁc mortality curves from Gambia and Malawi.
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Non-speciﬁc effects of DTPon child survival. VAS at birth is not WHO policy, and
among children who had not received VAS at birth, early
MV compared with DTP3 as the most recent vaccination
was associated with a threefold reduction in mortality
between 4.5 and 9 months of age (MRR ¼0.33 (95% CI
0.13 to 0.86)), the estimate being 0.30 (95% CI 0.07 to
1.31) for girls and 0.36 (95% CI 0.10 to 1.26) for boys.
Second test: booster BCG vaccination
Since booster DTP and OPV are usually administered at
18 months of age in Guinea-Bissau, we enrolled children
at 19 months of age in a trial of BCG revaccination.
69
Among children who had received booster DTP before
enrolment, BCG revaccination was associated with
a threefold reduction in mortality, the MRR being 0.36
(95% CI 0.13 to 0.99)
69 with a similar effect in girls and
boys. Children who had not received booster DTP before
enrolment were encouraged by health personal to come
back and receive missing DTP vaccinations. In this
group, BCG revaccination was associated with increased
mortality, the MRR being 1.78 (95% CI 1.04 to 3.04). In
general, the effect of BCG revaccination may have been
better for girls since girls had a signiﬁcantly lower risk of
hospitalisation than boys after BCG revaccination
(femaleemale hospitalisation ratio 0.65 (95% CI 0.46 to
0.93)), the annual incidence rates being 3.1% for girls
and 4.8% for boys. Among controls, the femaleemale
hospitalisation ratio was 1.00 (95% CI 0.70 to 1.43), the
incidence rates being 3.8% for both girls and boys.
69
Methodological considerations and implications
Since live vaccines usually have a good effect for girls, the
proposed changes in vaccination schedule represented
attempts to reduce the negative effects by administering
live vaccines after inactivated DTP. Both randomised
studies showed an effect consistent with our hypothesis;
bias is unlikely to have had any effect. Both studies also
showed that there may be unimagined interactions with
other immune interventions; in the MV trial, neonatal
VAS removed the beneﬁcial effect of early MV, and in the
BCG revaccination trial, getting DTP after BCG revacci-
nation doubled mortality. It is not possible to determine
whether the beneﬁcial effect of early MV or BCG revac-
cination is due to a reduction in the negative effect of
DTP or to beneﬁcial NSE of these vaccines. However,
both studies suggest that it is beneﬁcial to reduce
exposure to DTP as most recent vaccination by using
a live vaccine.
DISCUSSION
Main ﬁndings
Our observations are not compatible with DTP merely
preventing the targeted diseases. Observations I, II and
IVeVI indicate that mortality is increased after DTP
vaccination compared with children who have BCG or
MVas their most recent vaccination. Observations IIIeVI
suggest that DTP has sex-differential effects on mortality,
the negative effect of DTP being worse for girls. Hence,
most excess mortality associated with DTP is due to
increased female mortality. As summarised in table 3,
most studies reﬂect what happens when DTP is admin-
istered after BCG or MV. In both situations, DTP is
associated with an increase in overall mortality, the effect
being particularly negative for girls. One study
42 suggests
that the effect of DTP is also negative when it is given to
totally unvaccinated children (table 3).
To test the implications of these observations, we
conducted two trials to reduce the time of exposure to
DTP as the most recent vaccination by administering MV
or BCG shortly after the last DTP vaccination. The effect
was beneﬁcial in both trials. These results are in glaring
contradiction to the increasing number of randomised
trials showing that BCG and MV have beneﬁcial NSE in
high-mortality countries.
36 56 97 98 1The randomised
trials conﬁrm previous observational studies of the
beneﬁcial effects of BCG and MV.
Strengths and weaknesses
In spite of the limitation of observational studies and the
variability in how the different data sets were collected,
the studies produced consistent results. Most observa-
tions were repeated in several studies and generated new
deductions, which were tested in all the available data
sets. Furthermore, several randomised trials or re-inter-
pretations of randomised trials now support the
hypothesis that DTP has negative effects, particularly for
girls.
55 15 26 97 2 e74
Table 3 Evidence for the effect of DTP in relation to the sequence of vaccinations
Sequence of vaccines:
most recent vaccination
before DTP
Effect on overall child
mortality Effect on female mortality Effect on male mortality
Unvaccinated Result: increased mortality
Evidence: ref.
42
Result: no signiﬁcant negative
effect
Evidence: ref.
42
Result: no signiﬁcant negative
effect
Evidence: ref.
42
BCG Result: increased mortality
Evidence: observations I, II
Result: increased mortality
Evidence: observations IeIII
Result: no signiﬁcant negative
effect
Evidence: ref.
43
Measles vaccine Result: increased mortality
Evidence: observations IV, V
Result: increased mortality
Evidence: observations IV, V
Result: no effect
Evidence: observation V
DTP, diphtheriaetetanusepertussis.
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Non-speciﬁc effects of DTPThe inherent tendency is to dismiss observations
conﬂicting with the current disease-speciﬁc paradigm as
probably due to uncontrolled confounding.
90 93
However, confounding is unlikely to explain the twofold
increase in mortality in the only community study of the
introduction of DTP,
42 the threefold decrease in hospital
case death when DTP was missing,
43 the fourfold increase
in mortality when DTP was given after BCG in a trial of
early BCG vaccination to LBW children,
64 the twofold
increase in mortality when DTP was administered after
HTMV
5 or standard MV (supplementary table 6) and the
twofold increase in mortality when vitamin A was given to
girls likely to receive DTP during follow-up.
74
Since our group produced most of these studies, it
could be said that these observations are due to publi-
cation bias because studies were published only if they
showed a negative effect of DTP.
93 Although this is not
the case, it is difﬁcult to provide evidence other than the
fact that all data sets reanalysed in collaboration with
other African research groups documented similar
patterns.
52 23 15 37 4
Analytical designs and conﬂicting interpretations
In the ﬁrst design, we compared DTP-vaccinated versus
DTP-unvaccinated children in a survival model
comparing sequential vaccinations at the same age.
Given the positive selection bias associated with DTP or,
alternatively, the frailty bias associated with not getting
DTP, the negative effect of DTP in all studies using
a landmark approach or caseecontrol design is note-
worthy.
61 Both the contrasting estimate for the different
vaccines and the natural experiment studies support the
hypothesis that DTP increases mortality. In contrast to
observations I and II, some studies using a sequential
vaccination comparison have produced beneﬁcial esti-
mates for DTP.
44e49 58 However, several of these studies
had survival bias due to retrospective updating of vacci-
nation status (table 2,
60 61). We obtained similar (falsely)
positive estimates for DTP when we reanalysed our own
data with survival bias.
62 Furthermore, these studies
mostly administered BCG and DTP simultaneously,
whereas we administered DTP after BCG as currently
recommended by WHO. We have shown in a rando-
mised trial of BCG at birth to LBW children that the
negative effect of DTP was much stronger among the
children who received BCG at birth and DTP 6e7 weeks
later than among children who received BCG and DTP
more or less at the same time.
64 Finally, social selection
and frailty bias were important in the studies that
produced beneﬁcial estimates for DTP.
46 59
In the second design, we compared the mortality rates
of girls and boys, and all studies suggested that mortality
is relatively increased for girls when DTP is the most
recent vaccination, whereas the opposite is true after
BCG and MV vaccinations. These studies are methodo-
logically less complicated as long as we can be sure that
the children are unlikely to receive other vaccinations
during follow-up. There is no clear indication of
a gender-speciﬁc selection bias which could explain this
pattern, and the fact that the femaleemale MRR is
increased after DTP but reduced after MV and BCG
excludes the possibility that these patterns are mainly
due to selection bias. It has been suggested that the
higher femaleemale MRR after DTP could be due to
reduced male mortality after DTP.
94 However, several of
our observations demonstrate that this is not the expla-
nation. First, DTP administered after BCG is associated
with increased mortality in both boys and girls (obser-
vations I and II). Second, mortality was increased twofold
when girls received DTP/IPV after HTMV (observation
IV) or after standard MV, while this was not the case for
boys (observation V). Third, female mortality is reduced
once DTP-vaccinated girls get MV (observation VI).
Interpretation
Our six observations on DTP are consistent with the
hypothesis that DTP without simultaneous administra-
tion of BCG or MV has a negative effect for girls
compared with both DTP-unvaccinated girls and
DTP-vaccinated boys.
80 Furthermore, we deduced the
hypothesis that DTP after MV might have been
the explanation of the increase in female mortality in
the HTMV trials, and the results of all the available
studies are consistent with this hypothesis (observation
IV). We also deduced that if an inactivated vaccine like
DTP were associated with higher femaleemale MRR,
similar effects might occur with other inactivated
vaccines. Both hepatitis B vaccine and IPV were associ-
ated with increased female mortality.
37 51 Though it has
not been possible to conduct a randomised trial of
delaying the primary series of DTP vaccinations, we did
randomise children at 4.5 months of age to early MV in
an attempt to reverse the adverse effect of DTP and we
achieved a threefold reduction in mortality.
3 Likewise,
BCG revaccination after DTP booster vaccination
reduced mortality threefold.
69 It is unlikely that DTP has
no negative sex-differential effects when such consistent
deductions can be generated.
The majority of studies have been conducted in
communities with herd immunity sufﬁcient to eliminate
deaths from whooping cough, and our studies do not
reﬂect what would happen in a situation without general
DTP vaccinations. There are very few community studies
that have assessed the impact of pertussis on child
mortality in high-mortality countries in the pre-vaccina-
tion era. The best community study was conducted in the
1970s in Kenya in the initiation phase of the vaccination
programme; the case death was assessed to be 1.3% for
all ages and pertussis was 6% of the infant deaths.
95
Given the major increases in mortality in observational
studies and the reduction in mortality in the randomised
studies, it seems likely that DTP would also be associated
with increased mortality for girls in situations without
herd immunity.
Possible biological mechanisms of NSE
Our work is based on the hypothesis that a vaccine may
affect the immune system in a sex-differential manner
20 Aaby P, Benn C, Nielsen J, et al. BMJ Open 2012;2:e000707. doi:10.1136/bmjopen-2011-000707
Non-speciﬁc effects of DTPduring the period when it is the most recent vaccina-
tion.
80 Studies of speciﬁc infections suggest that vaccines
may enhance or reduce susceptibility to these unrelated
infections in a sex-differential manner.
38 55 56 75
Presumably, the NSE could also be due to changes in the
control of infections, with vaccines enhancing or
reducing the severity of subsequent infections. This
possibility has yet to be examined in epidemiological
studies.
Immunological studies have shown that vaccines may
inﬂuence the response to unrelated antigens. In animal
studies, inactivated vaccines like DTP are associated with
a Th2 proﬁle, whereas live vaccines of the same antigens
produce a Th1 proﬁle, and this difference is important
for the response to a subsequent challenge.
96e103 This
difference may be more important for girls.
102 In animal
studies, some infections prime the immune response to
other pathogens, resulting in so-called heterologous
immunity, which may be either protective or detri-
mental.
4 104 Some human infections may have a similar
importance; for example, we have found in several
studies that measles infection may reduce the mortality
from other causes after the acute phase of measles
infection.
19 105 106 Furthermore, the very rapid reduction
in mortality in randomised trials of BCG vaccination at
birth suggests that BCG is training the innate rather than
the adaptive immune system in a beneﬁcial manner.
79 107
However, it may still be difﬁcult to believe that a single
vaccination like BCG, DTP or MVdin an environment
with numerous concurrent and competing infectionsd
could have such profound sex-differential NSE on overall
mortality. However, the vaccines with strong NSE are all
given by parenteral injection, which bypasses the natural
immune barriers, and this could have an important
inﬂuence on their effects on the immune system.
Other factors affecting the immune system may inﬂu-
ence the NSE of DTP, for example, season, other
vaccines and micronutrient interventions.
70e74 76 We
have already alluded to the fact that combinations of
DTP and BCG, or DTP and MV, have distinct effects,
which cannot be deduced from the patterns described in
the present hypothesis.
5
Conclusions and implications
There are no deﬁnite criteria for imputing causality in
observational studies, though the Hill criteria
108 are
often invoked. The present data on DTP comply with the
criteria of strength of association, doseeresponse rela-
tionship,
27 42 temporal sequence, consistency between
different studies and speciﬁcity of the association. Most
people would also request biological plausibility.
However, as Hill noted, only biological processes that are
already known are plausible.
108 When exploring
a phenomenon with unknown biological mechanisms,
the main criterion for scientiﬁc fruitfulness is consis-
tency of observations. We developed six linked hypoth-
eses, which suggest that DTP is consistently associated
with higher female mortality. Furthermore, we
conducted two randomised trials to reduce exposure to
DTP, and both trials suggested that this was beneﬁcial. If
randomised trials are deemed unethical, the present
study represents the best possible evidence for the
hypothesis that one of the most widely used routine
vaccines has negative sex-differential effects. The ﬁnding
that DTP has adverse effects has several implications.
International organisations and donors have chosen to
use DTP3 coverage as the main indication of the effec-
tiveness of national vaccination programmes.
109 110 This
leads to DTP vaccination campaigns and to vaccinations
being administered out of sequence.
66 Both DTP vacci-
nations before 9 months of age and DTP administered
after MV suggest that DTP is associated with many
unnecessary deaths. Given the potential for negative
effects from DTP, MV coverage should be used to
monitor the effectiveness of national vaccination
programmes rather than DTP coverage.
Randomised trials are warranted to assess the ‘true’
impact of DTP on child survival.
82 First, several obser-
vational studies have found that early DTP vaccination is
particularly harmful.
55 64 and it would therefore be
desirable to examine whether delaying DTP vaccinations
reduces this negative effect (WGNSEV, trial 6). However,
this design is likely to be particularly controversial,
85
and it may therefore be more strategic to further test
whether an early two-dose MV schedule at 4 and
9 months can improve child survival (WGNSEV, trial 2).
3
Second, administering DTP with or after MV may be
harmful,
22 44 53 57e59 66 77 and trials are therefore needed
to assess whether the vaccination programme should
forbid such out-of-sequence vaccinations (WGNSEV, trial
4). Third, SAGE (WHO Strategic Advisory Group of
Experts on immunisation) has recently recommended
a booster dose of pertussis vaccine given in the second
year of life.
111 This recommendation could increase
mortality (see ﬁgure 10). As suggested by the WGNSEV,
the effect of a booster dose of pertussis should be tested
in a randomised controlled trial (RCT) measuring the
impact on overall survival by providing a live vaccine
shortly after booster DTP (trial 3).
82 Alternatively, before
being introduced, a booster dose of DTP should be
tested in a randomised trial.
We should also consider whether immunity to DTP
could be obtained with a different vaccine having no
negative effects in a situation with herd immunity.
112 In
the current vaccination schedule (see ﬁgure 1), DTP is
the most recent vaccination for 49.5 months for the ﬁrst
5 years of life if booster DTP is given and for 7.5 months
if no booster is given. This could be reduced to 3e4
months if an additional dose of MV were given at
4 months of age and a live vaccine were given 1 month
after a DTP booster. This could be further reduced if the
initial series of three doses of DTP were reduced to two
doses in countries with a booster dose of DTP.
The WGNSEV recommended six trials to assess the
beneﬁcial effects of BCG and MV and the potential
negative effects of DTP. The three priority trials (trials
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Non-speciﬁc effects of DTP1e3) have been completed and have clearly shown that
NSE are important. A small trial similar to trial 4 has also
found negative effects of DTP.
77 The two remaining trials
(trials 5e6) are less relevant or feasible. Trial 5 would
test DTP without aluminium, but this could not be done
without major funding to get a new vaccine licensed.
Trial 6 tests a delayed DTP schedule, which is contro-
versial and has become less relevant due to the beneﬁcial
effect of early MV.
3 Hence, to advance the under-
standing of the NSE of vaccines, the most important
steps may be that other groups repeat the three priority
trials.
82 Many new vaccines are being tested and intro-
duced at the moment. It would seem important that
potential NSE and sex-differential effect of the new
vaccines be tested through carefully controlled beforee
after studies, phased introduction studies or randomised
trials.
The global health community has conducted no trial
to document that BCG, DTP, OPV and MV have the
intended effects on child survival and only those effects.
Randomised controlled trials have now shown major
beneﬁcial NSE of BCG and MV
36 56 97 9and negative
effects of HTMV.
5 The common assumption that
vaccines have mainly disease-speciﬁc preventive effects is
no longer tenable. The data presented here suggest that
DTP has a negative effect for girls. Experts have recog-
nised that WHO-sponsored studies reporting a beneﬁcial
effect of DTP had methodological problems,
113 and
Global Advisory Committee on Vaccine Safety has
declared that it will keep a watch on the evidence of NSE
of vaccines, including a potential deleterious effect of
DTP vaccination.
114 Despite this, policy has not changed
and studies have not been organised to resolve the
issues. In a culture that prides itself on being evidence
based, such inconsistencies between policy and evidence
should not be acceptable. We can only hope that the
global health community will seek to establish the much-
needed evidence for the current vaccination policies to
ensure that immunisation confers maximum beneﬁt on
children in high-mortality countries.
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